| Literature DB >> 18466445 |
Kimberly E Taylor1, Wei Chen, Christopher I Amos, Lindsey A Criswell.
Abstract
We applied nonparametric quantitative trait linkage analysis to two rheumatoid arthritis quantitative phenotypes, IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide autoantibody titer measurements, using 5700 genome-wide Illumina single-nucleotide polymorphism genotypes on 658 Caucasian North American Rheumatoid Arthritis Consortium families. Peak LOD scores for both quantitative traits were located in the human leukocyte antigen region 6p21 (15.8 and 13.8 for RF and anti-cyclic citrullinated peptide, respectively) followed by 11p12 (3.2 and 3.6). In addition, there were LOD scores of 3.2 on 2q32 for RF and 3.6 on 4q24 for anti-cyclic citrullinated peptide. The resulting linkage signals for both phenotypes are very similar to previous results for rheumatoid arthritis as a qualitative variable, with rheumatoid factor measurements being most closely aligned. Interestingly, anti-cyclic citrullinated peptide exhibits a stronger linkage peak on 2p14 than rheumatoid factor and rheumatoid arthritis, and stronger linkage on 4q24. Finally, we used ordered subset analyses to determine if sub-ranges of these two traits increased rheumatoid arthritis linkage signals; however, our analyses did not reveal significant effects of the quantitative traits on rheumatoid arthritis linkage signals in this population.Entities:
Year: 2007 PMID: 18466445 PMCID: PMC2367581 DOI: 10.1186/1753-6561-1-s1-s105
Source DB: PubMed Journal: BMC Proc ISSN: 1753-6561
Peak LOD scores and locations with/without LD clusters.
| Without LD clusters | With LD clusters | ||||
| Trait | Chromosome | Peak LOD | Locations (kb) | Peak LOD | Locations (kb) |
| Anti-CCP | 2 | 3.1 | 70859 | 2.8 | 66769, 67023 |
| 4 | 4.4 | 104210 | 104353 | ||
| 6 | 14.9 | 28965 | 32992 | ||
| 11 | 4.4 | 39183, 39201 | 40486 | ||
| 21 | 8.3 | 37442, 37455 | 2.4 | 40861 | |
| RF | 2 | 3.2 | 194143 | 194143 | |
| 5 | 3.6 | 13709, 13735 | 2.6 | 13722 | |
| 6 | 18.4 | 28965 | 32992 | ||
| 10 | 3.4 | 60473, 60475 | 2.6 | 75017 | |
| 11 | 4 | 39201 | 41024 | ||
| 12 | 3.7 | 131968, 132017 | 1.6 | 22217 | |
| 19 | 4.5 | 63636, 63638 | 0.2 | 61193, 61823 | |
| 21 | 11.8 | 37433–37442 | 1.5 | 40861 | |
| 23-X | 3.2 | 56386–56493 | 0.83 | 10450 | |
aUsing same set of subjects as anti-CCP analyses
Figure 1RF and anti-CCP linkage on chromosome 2 for affected subjects having measurements for both traits.
Figure 2RF and anti-CCP linkage on chromosome 4 for affected subjects having measurements for both traits.
Figure 3RF and anti-CCP linkage on chromosome 6 for affected subjects having measurements for both traits.
Figure 4RF and anti-CCP linkage on chromosome 11 for affected subjects having measurements for both traits.